<DOC>
	<DOCNO>NCT01729624</DOCNO>
	<brief_summary>A qualitative study use interview patient antineutrophil cytoplasm antibody ( ANCA ) associate vasculitis , develop patient report outcome ( PRO ) measure</brief_summary>
	<brief_title>PRO Development ANCA Associated Vasculitis</brief_title>
	<detailed_description>Patients antineutrophil cytoplasmic antibody ( ANCA ) associate vasculitis ( AAV ) inflammation small blood vessel lead involvement different body area , e.g. , kidney , lung skin . Untreated , risk death 80 % ; current treatment , patient often suffer ongoing disease activity , damage treatment side effect negative impact quality life . Because patient AAV wide range disease feature , investigator hypothesise general patient report outcome ( PROs ) measurement , may specific enough describe full impact quality life . The main objective project start patient ' experience develop disease specific PRO patient AAV . Patients diagnose AAV recruit clinic inpatient Oxford University Hospitals ( OUH ) National Health Service ( NHS ) Trust , , patient previously consent contacted future study , Diagnostic Classification Vasculitis ( DCVAS ) The Characterisation Determinants Quality Life ANCA Associated Vasculitis ( VasQoL ) study database . After informed consent obtain , individual patient interview conducted; last approximately one hour record transcribed . Themes independently extract amalgamated researcher . Approximately 25 patient different type ANCAassociated vasculitis vary disease duration interview saturation , i.e. , new substantive theme emerge . These theme evolve individual candidate questionnaire item . Candidate item pilot approximately 25 different patient AAV use questionnaire interview , comment arise , produce final set candidate questionnaire item . The duration study 1.5 year .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Antibodies , Antineutrophil Cytoplasmic</mesh_term>
	<criteria>Participant willing able give inform consent participation study . Male female Aged 18 year ( upper limit ) . Diagnosed granulomatosis polyangiitis Wegeners ( GPA ) , Churg Strauss Syndrome ( CSS ) microscopic polyangiitis ( MPA ) fulfil either Chapel Hill consensus conference definition American College Rheumatology ( ACR ) classification criterion . Unable unwilling give independent write informed consent Significant communication barrier e.g. , inability speak English Membership steer committee</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Wegener Granulomatosis</keyword>
	<keyword>Microscopic Polyangiitis</keyword>
	<keyword>Churg-Strauss Syndrome</keyword>
	<keyword>Antibodies , Antineutrophil Cytoplasmic</keyword>
</DOC>